Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: Evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen

Cancer

Volumn 113, Issue 5, 2008, Pages 945-955

  Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chemotherapy; Docetaxel; Gastroesophageal cancer; Locally advanced; Metastatic

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CIPROFLOXACIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; OXALIPLATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; TAXOID;

ADD ON THERAPY; ADVANCED CANCER; ANEMIA; ANOREXIA; ARTERY THROMBOSIS; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; INFECTION; INFORMATION RETRIEVAL; LETHARGY; LEUKOPENIA; LOW DRUG DOSE; LOWER ESOPHAGUS SPHINCTER; MAXIMUM TOLERATED DOSE; MEDLINE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PATIENT SAFETY; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK REDUCTION; SEPTICEMIA; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOMA; STOMATITIS; SYNCOPE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; EVALUATION; REVIEW; STOMACH TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS AS TOPIC; ESOPHAGOGASTRIC JUNCTION; FLUOROURACIL; HUMANS; STOMACH NEOPLASMS; TAXOIDS;

EID: 52049087904     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23661     Document Type: Article

References (62)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across 5 continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137-2150.
2. National Cancer Institute. SEER database. Available at: http://seer.cancer.gov/statfacts/html/stomach.html Accessed April 10, 2007.
3. Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol. 2005;2:98-107.
4. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049-2053.
5. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12:354-362.
6. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903-2909.
7. Sulkes A, Smyth J, Sessa C, et al. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer. 1994;70:380-383.
8. Einzig AI, Neuberg D, Remick SC, et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol. 1996;13:87-93.
9. Taguchi T, Sakata Y, Kanamaru R, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A). Gan To Kagaku Ryoho. 1998;25:1915-1924.
10. Mai M, Sakata Y, Kanamaru R, et al. A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B). Gan To Kagaku Ryoho. 1999;26:487-496.
11. Vanhoefer U, Wilke H, Harstrick A, et al. Phase II study of docetaxel as second-line chemotherapy in metastatic gastric cancer. Proc Am Soc Clin Oncol. 1999. Abstract 1163.
12. Graziano F, Catalano V, Baldelli AM, et al. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol. 2000;11:1263-1266.
13. Mavroudis D, Kourousis C, Androulakis N, et al. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. Am J Clin Oncol. 2000;23:341-344.
14. Bang YJ, Kang WK, Kang YK, et al. Docetaxel 75 mg/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol. 2002;32:248-254.
15. Giuliani F, Gebbia V, De Vita F, et al. Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). Anticancer Res. 2003;23:4219-4222.
16. Lee J, Ryu M, Kang H, et al. Efficacy and safety study of docetaxel as salvage chemotherapy in metastatic gastric cancer failing fluoropyrimidine and platinum combination chemotherapy. J Clin Oncol. 2005;22(suppl 16S):4220.
17. Roth AD, Maibach R, Martinelli G, et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK),and the European Institute of Oncology (EIO). Ann Oncol. 2000;11:301-306.
18. Roth AD, Maibach R, Fazio N, et al. 5-fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial. Ann Oncol. 2004;15:759-764.
19. Roth AD, Fazio N, Stupp R, et al. Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007;25:3217-3223.
20. Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005;23:5660-5667.
21. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24:4991-4997.
22. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 study group. J Clin Oncol. 2007;25:3210-3216.
23. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 study group. J Clin Oncol. 2007;25:3205-3209.
24. Smith T, Khatcheressian J, Lyman G, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187-3205.
25. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433-2453.
26. National Comprehensive Cancer Network. Practice guidelines in oncology: Myeloid growth factors. V.I. 2007. Available at: http://www.nccn.org/ professionals/physician_gls/PDF/myeloid_growth.pdf Accessed April 20, 2007.
27. Vogel C, Wojtukiewicz M, Carroll R, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178-1184.
28. Martin M, Lluch A, Segui M, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte colony-stimulating factor to the TAC regimen. Ann Oncol. 2006;17:1205-1212.
29. Von Minckwitz G, Blohmer J, Lohr A, et al. Primary prophylaxis with 3 weekly pegfilgrastim and ciprofloxacin effectively prevent (febrile) neutropenia and infection during neoadjuvant chemotherapy with docetaxel/doxorubicin/ cyclophosphamide (TAC) in breast cancer patients. Presented at the American Society of Clinical Oncology 43rd Annual Meeting, Chicago, Ill, June 1-5, 2007. J Clin Oncol. 2005;23:(16 suppl):4220.
30. Tebbutt N, Sourjina T, Strickland A, et al. ATTAX: randomized multicenter phase III study evaluating weekly docetaxel-based chemotherapy combinations in advanced esophago-gastric cancer, final results of an AGITG trial. Abstract 4528. Presented at the American Society of Clinical Oncology 43rd Annual Meeting, Chicago, Ill, June 1-5, 2007. J Clin Oncol. 2008;23(16 suppl):8008.
31. Orditura M, Martinelli E, Galizia G, et al. Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study. Ann Oncol. 2006;17:1529-1532.
32. Lorenzen S, Hentrich M, Haberl C, et al. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol. 2007;18:1673-1679.
33. Park SR, Chun JH, Kim YW, et al. Phase II study of lowdose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma. Am J Clin Oncol. 2005;28:433-438.
34. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother. 2003;4:889-901.
35. Eriguchi M, Nonaka Y, Yanagie H, et al. A molecular biological study of anti-tumor mechanisms of an anti-cancer agent oxaliplatin against established human gastric cancer cell lines. Biomed Pharmacother. 2003;57:412-415.
36. Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol. 1998;25:4-12.
37. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol. 1996;52:1855-1865.
38. Raymond E, Faivre S, Chaney S, et al. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther. 2002;1:227-235.
39. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
40. Cunningham D, Starling N, Rao S, et al. Randomised multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: the REAL 2 trial. N Engl J Med. 2008;358:36-46.
41. Richards D, McCollum D, Wilfong L, et al. Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction. Ann Oncol. 2008;19:104-108.
42. Barone C, Basso M, Schinzari G, et al. Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. Gastric Cancer. 2007;10:104-111.
43. Hejna M, Zacheri J, Ba-Ssalamah A, et al. Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously treated with chemotherapy for advanced disease. Results of the CECOG-Study ESGAS. 1.2.001. Abstract 4527. Presented at the American Society of Clinical Oncology 43rd Annual Meeting, Chicago, Ill, June 1-5, 2007.
44. Al-Batran S, Hartmann JT, Hofheinz R, et al. Modified FOLFOX in combination with docetaxel for patients with metastatic adenocarcinoma of the stomach or gastroesophageal junction: a multicenter phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Abstract 4545. Presented at the American Society of Clinical Oncology 43rd Annual Meeting, Chicago, Ill, June 1-5, 2007.
45. Dima G, Caputo A, De Simone R, et al. Phase II study of docetaxel, oxaliplatin, and folinic acid in locally advanced or metastatic gastric cancer patients [abstract]. Ann Oncol. 2005;15(suppl 7):Page. Abstract E27.
46. Ajani JA, Phan AT, Ho L, et al. Phase I/II trial of docetaxel plus oxaliplatin and 5-fluorouracil (D-FOX) in patients with untreated, advanced gastric or gastroesophageal cancer. Abstract 4612. Presented at the American Society of Clinical Oncology 43rd Annual Meeting, Chicago, Ill, June 1-5, 2007.
47. Di Lauro L, Nunziata C, Arena MG, et al. Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma. Br J Cancer. 2007;97:593-597.
48. Cunningham D. Is oxaliplatin the optimal platinum agent in gastric cancer. Eur J Cancer Supplements. 2006;4:10-13.
49. National Institutes of Health. ClinicalTrials.gov. Available at: http://www.clinicaltrials.gov/ct/show/NCT00382720?order=1 Accessed April 2007.
50. National Institutes of Health. ClincalTrials.gov. Available at: http://www.clinicalTrials.gov/ct/show/NCT00217581?order=1 Accessed April 2007.
51. Van Cutsem E. Novel cytotoxic regimens in gastric cancer. Eur J Cancer Supplements. 2006;4:14-18.
52. National Institutes of Health. ClinicalTrials.gov. Available at: http://www.clinicaltrials.gov/ct/show/NCT00448760?order=1 Accessed April 2007.
53. Chun JH, Kim HK, Lee JS, et al. Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol. 2005;28:188-194.
54. Giordano KF, Jatoi A, Stella PJ, et al. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Ann Oncol. 2006;17:652-656.
55. Kim JG, Sohn SK, Kim DH, et al. Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. Oncology. 2005;68:190-195.
56. Lorenzen S, Duyster J, Lersch C, et al. Three-weekly docetaxel (T) plus capecitabine (X) in 1st and 2nd line metastatic esophageal cancer (MEC): final results of the Phase II DACAPO trial [abstract]. J Clin Oncol. 2005;23(suppl 16):343s. Abstract 4142.
57. Thuss-Patience PC, Kretzschmar A, Loew A, et al. Capecitabine and docetaxel in advanced gastric adenocarcinoma, an ongoing phase II study [abstract]. J Clin Oncol. 2005;23(suppl 16):343s. Abstract 4224.
58. Evans D, Miner T, Iannitti D, et al. Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study. Cancer Invest. 2007;25:445-448.
59. Sakata Y, Ohtsu A, Horikoshi N, et al. Late Phase II study of novel oral fluoropyrimidine anticancer drug S-1 in advanced gastric cancer. Br J Cancer. 1998;34:1715-1720.
60. Koizumi W, Tanabe S, Saigenji K, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer. 2003;89:2207-2212.
61. Yoshida K, Ninomiya M, Takakura N, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res. 2006;12:3402-3407.
62. Enzinger PC, Fidias P, Meyerhardt J, et al. Phase II study of bevacizumab and docetaxel in metastatic oesophageal and gastric cancer. Abstract 68. Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, Calif, January 26-28, 2006.